In this analysis of multiple studies of BV in systemic and cutaneous T- and B-cell NHL, clinical benefit from BV was observed in patients with all levels of CD30 expression, including in patients with no visually detectable CD30 expression by IHC on at least one biopsy. This evidence concerns the gene TNFRSF8 and bacterial vaginosis.